Atlas Trials

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Clinical trial NCT04493853 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04493853
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hormone-Sensitive Prostate Cancer
Start date
2020-07-13
Primary completion
2024-10-07
Enrollment
1012

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.